Outcome of Board meeting held on 13.11.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved unaudited financial results for the quarter and half-year ended 30 September 2025. Standalone numbers show severe distress: Q2 revenue collapsed to Rs. 32.93 lakhs from Rs. 316.61 lakhs a year ago (~90% decline) and the company posted a standalone net loss of Rs. 34.74 lakhs in Q2 (vs profit of Rs. 33.08 lakhs last year). H1 standalone loss widened to Rs. 61.63 lakhs, and standalone other equity has turned negative at Rs. (51.34) lakhs vs Rs. 10.25 lakhs at March 2025. Cash flow from operations was negative Rs. 17.61 lakhs (H1 standalone). Consolidated numbers look far healthier because subsidiary VSR Paper & Packaging (55% holding) is the real driver – Q2 consolidated revenue jumped ~51% YoY to Rs. 1,222.83 lakhs and Q2 PAT rose sharply to Rs. 14 lakhs, though H1 consolidated PAT actually fell to Rs. 6.02 lakhs vs Rs. 67.19 lakhs. Auditor M M Reddy & Co. issued an unqualified limited review report on both sets of results.
Standalone pharma business is in clear trouble with shrinking top line, losses and negative net worth — minority shareholders effectively depend entirely on the paper packaging subsidiary. Consolidated total borrowings (~Rs. 2,189 lakhs) against equity of ~Rs. 1,593 lakhs mean the group is also fairly leveraged, so any further slowdown in the subsidiary could weigh on the stock. Near-term, the headline deterioration in standalone results is the main negative signal for investors.